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Summary box
 ► The international community has pledged through 
the Sustainable Development Goals to eliminate ne-
glected tropical diseases by 2030.
 ► Authors from 19 institutions around the world call for 
urgent reflection and a change in mind-set to garner 
support and hasten progress towards achieving this 
fast approaching target.
 ► They advocate for an empowering approach that will 
propel political momentum, milestones and targets 
for accountability, new science in drug develop-
ment and increased funding particularly from G20 
countries.
“We must become bigger than we have been: more 
courageous, greater in spirit, larger in outlook.”
Emperor Haile Selassie
It was in the city of Gondar in Ethiopia, one 
of the highest burden countries for neglected 
tropical diseases (NTDs)1 and currently home 
to 16 to 20 recognised NTDs (table 1), that 
a unanimous desire was expressed by scien-
tists, policy makers and health workers from 
around the world (the forum was an opera-
tional research training on NTDs organised 
by the Structured Operational Research and 
Training Initiative (SORT IT). SORT IT is a 
global partnership coordinated by the Special 
Programme for Research and Training in 
Tropical Diseases (TDR) hosted at the WHO. 
http://www. who. int/ tdr/ capacity/ strength-
ening/ sort/ en), for urgent reflection on how 
to garner support and hasten the pace towards 
achieving the fast approaching Sustainable 
Development Goal (SDG) target of elimi-
nating NTDs by 2030.2 Concerns, raised by 
the group are articulated below:
First, there is the term ‘Neglected Trop-
ical Diseases’, coined by Peter Hotez and 
colleagues in 2003 with the noble intention 
of propelling political momentum, cata-
lysing donor funding and making quantum 
shifts in research and development (R&D).3 
The question today is whether designating a 
specific group of diseases as being ‘neglected’ 
does not carry with it a negative and disem-
powering connotation. Populations affected 
by NTDs already face neglect by being the 
world’s poorest and facing social stigmatisa-
tion, prejudice and marginalisation. Lacking 
a ‘strong political voice’, these communities 
have a low profile and status in public health 
priorities.4 Having the label of ‘neglected’ 
added to their illnesses may accentuate their 
predicament. Put simply, how can human 
beings, who risk being diminished by being 
designated as ‘neglected’ by us in the health 
system, be considered equal partners in their 
own care? Language is more than words: it 
has the power to transform the way people 
think and behave.5
This term may thus allow politicians and 
donors to maintain a ‘business-as-usual’ 
mode by accepting the idea of neglect 
as an unchangeable paradigm, damp-
ening the drivers behind political impetus 
and funding. The quote from a SORT IT 
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Table 1 The 20 neglected tropical diseases recognised by 
the WHO*
Category Disease
Protozoan infections 1. Chagas disease
2. Human African trypanosomiasis
3. Leishmaniasis
Helminth infections 4. Taenia solium (neuro) cysticercosis/
Taeniosis
5. Dracunculiasis
6. Echinococcus
7. Foodborne trematodiases
8. Lymphatic filariasis
9. Onchocerciasis
10. Schistosomiasis
11. Soil-transmitted helminthiases 
(ascariasis, Hookworm diseases, 
trichuriasis, strongyloidiasis)
Bacterial infections 12. Buruli ulcer
13. Leprosy
14. Trachoma
15. Yaws
Viral infections 16. Dengue and chikungunya fevers
17. Rabies
Fungal Infections 18. Mycetoma, chromoblastomycosis, 
deep mycosis
Ectoparasitic 
infections
19. Scabies, Myiasis
Venom 20. Snakebite envenoming
*Source. World Health Organisation. Neglected Tropical 
Diseases 2017 https://www.who.int/neglected_diseases/
diseases/en/.
participant was illustrative ‘I hoped to do my PhD on intes-
tinal worms, but I was quickly dissuaded by many in academic 
and government circles saying it is a neglected disease’.
The Amharic (Ethiopian) translation of NTDs reads 
‘Tropical diseases needing special attention’- an empow-
ering designation with an imperative for action which 
reflects the mind-set change that is urgently needed.
Second, the 15 years of naming this constellation 
of diseases of poverty as ‘Neglected Tropical Diseases’ 
have not really changed the paradigm, as we have only 
kept adding to the list of NTDs with none coming 
off permanently.6 7 This is proof that much more is 
needed to eliminate NTDs, including clear objective 
criteria for getting on or off the list. Furthermore, since 
being removed from the NTD list may be a disincen-
tive for continued funding support it may encourage 
passiveness.
Bringing NTDs into the SDG agenda is laudable, 
but strong activism and political momentum is now 
urgently needed.8 HIV/AIDS is a good example. The 
‘3 by 5’ initiative, launched by the Joint United Nations 
Programme on HIV/AIDS (UNAIDS) and WHO in 
2003, was a global target to provide life-prolonging 
antiretroviral treatment (ART) to three million people 
living with HIV/AIDS in low-income and middle-in-
come countries by the end of 2005.9 This was followed 
by Universal Access targets, the Treatment 2.0 Strategy 
and the UNAIDS 90-90-90 treatment targets. All of 
these were important drivers that simplified therapy, 
increased treatment coverage and crystallised the 
necessary environment for the establishment of opera-
tional and programmatic components for an expanded 
and sustainable global response to HIV/AIDS.10 From 
hundreds on ART in 2003, the result was 21.7 million 
on ART by 2017.11 Such initiatives reached fruition 
because of a public health approach to ART scale-up 
as part of Universal Health Coverage (UHC). It is time 
to gear similar political and funding impetus towards 
NTDs. Since the NTD package includes a diversity of 
diseases, the role of disaggregated or appropriately 
combined treatment targets may help.
Third, the list of NTDs is diverse, with parasitic, 
bacterial, viral, fungal infections and snakebite enven-
oming.3 Unlike diseases such as HIV/AIDS, TB and 
Malaria, there are practical difficulties in building 
strong communities of practice, as NTD work is often 
confined to silos of specific diseases.4 While recognising 
the specificities of each condition, new ways of building 
an integrated approach that compels stake holders to 
look beyond ‘the trees to see the forest’ are needed.
The WHO Roadmap strategy on control, elimina-
tion and eradication of NTDs is commendable, but it 
is geared only until 2020 and urgent work is needed to 
align it with the 2030 SDG target.8 11 Importantly, the 
road map is largely focused on the diseases for which 
medicines and large-scale prevention and treatment 
options exist, such as for onchocerciasis, lymphatic 
filariasis, schistosomiasis, soil-transmitted helminths 
(STH) and trachoma.12 Implementation of large-
scale prevention and treatment is often hampered 
by shortages of drugs and vaccines which needs to be 
addressed. Vector control activities are also required 
for vectorborne diseases, such as dengue and leish-
maniasis, while veterinary public health as part of the 
‘One Health’ approach is needed for zoonotic diseases, 
such as taeniasis/neuro-cysticercosis, echinococcosis 
and rabies. The provision of safe water, sanitation and 
hygiene (WASH) is another key component of the 
WHO strategy to overcome NTDs such as trachoma and 
STH. These interventions, and how they are integrated 
into broader health systems and within the principles 
of UHC, are spelt out in the WHO’s 4th comprehensive 
Report on NTDs, but in contrast to tuberculosis and 
HIV/AIDS, this lacks clear and measurable targets and 
milestones by which to judge progress.13 If we are to 
eliminate NTDs by, 2030 the ‘how to’ of this gigantic 
task needs to be defined including milestones and 
targets.
Finally, there is an urgent need for a quantum shift 
in funding for R&D and for treatment access. Despite 
evidence that interventions to address NTDs are one 
of the best health investments, only 0.6% of develop-
ment assistance for health is allocated to NTDs that 
affect about 1.5 billion people or roughly 20% of the 
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Figure 1 Impact of market on product pipeline (diagnostics, drugs vaccines) starting from the preclinical stage for various 
diseases.15 Type II diseases: are incident in both rich and poor countries with substantial proportion of the cases in poor 
countries.15 Type III disease: are those that are overwhelmingly or exclusively incident in developing countries.15 NTDs, 
neglected tropical diseases.
world population.14 This is clear evidence of inequity 
in global health financing which needs correction.14 
In 2015, WHO estimated that US$18 billion (US$3.6 
billion a year) was the investment target to achieve the 
NTD road map until 2020. The reality lies at less than 
US$ 200 million a year - a 94% yearly shortfall.8 11
Similarly, there is an inverse relationship between 
commercial market size and products in the R&D 
pipeline. NTDs lie towards the bottom of the pile 
(figure 1).15 A 2018 TDR publication drew attention to 
the fact that the current R&D pipeline is dominated by 
three diseases—malaria, HIV/AIDS and tuberculosis. 
For NTDs, 12 (57%) of 20 NTDs have nothing at all 
in the pipeline (figure 2).16 This finding reiterates the 
need to establish a new funding model for NTD-related 
R&D and the need for national and regional invest-
ments. Africa is the continent most affected by the NTD 
burden, but contributes less than 1% to global expendi-
ture on R&D.17 The BRICS (Brazil, Russia, India, China 
and South Africa) and G20 countries have an oppor-
tunity to show leadership in addressing this challenge. 
A possible way forward is to call on G20 countries to 
generate a special fund for NTDs since the NTD burden 
is highest among the poor in G20 countries (together 
with Nigeria) and they have capacity to develop generic 
products. Furthermore, NTDs are pervasive wherever 
poverty and vulnerable populations exist, including 
emerging market economies.18 If these countries 
would effectively implement NTD programmes, a large 
proportion of the NTD burden would be resolved.7 18 
NTD endemic populations are the least likely to be able 
to meet SDG targets that include UHC (target 3.8), 
safe water (target 6.1) and sanitation (target 6.2) and 
as such they can serve as tracers of equity in progress 
towards the SDGs.
Reflection on how existing global funding mecha-
nisms such as the Global Fund Against AIDS, TB and 
Malaria (GFATM) could also embrace NTDs as part of 
their portfolio is needed more than ever before. From 
an operational perspective, this seems logical as areas 
endemic for NTDs also tend to be endemic for HIV/
AIDS, tuberculosis and malaria. Coinfections with 
STH and schistosomiasis are also known to exacerbate 
the progression of the aforementioned diseases.19 A 
promising way of pushing the NTD agenda and lever-
aging political attention and resources would thus 
be an integrated management approach to NTDs, 
Malaria, Tuberculosis and HIV and a call for public 
health action at a broad level in countries. Such an 
approach would also strengthen the general health 
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Figure 2 Number of candidate products (diagnostics, drugs vaccines) for neglected diseases, by disease condition in 2017.
system with benefits to the management and control 
of NTDs.
When new drugs are developed for NTDs, they need 
to be deployed at programmatic level as quickly as 
possible, and here the funding support from GFATM 
for operational research would facilitate a win-win situa-
tion. Whatever the eventual choice may be, articulating 
the mechanisms for funding remains a glaring gap.
In conclusion, in countries like Ethiopia how well we 
do with NTDs could serve as ‘tracers of equity’ towards 
the SDGs and markers of the philosophy of ‘leaving 
none behind’. We must succeed, but that will depend 
on the backing of a supportive political environment, 
coupled with new science, funding (particularly by 
G20 countries) and robust advocacy. Most of all, we 
will need a greatly strengthened sense of global soli-
darity focused on the needs of the poorest and most 
vulnerable and with the participation of all countries, 
all stakeholders and all people.4 If we are to transform 
the NTD world for the SDGs, it will require us to first 
transform our thinking and actions.
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